Re: Zenith AGM Dec 15

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith AGM Dec 15

in response to

Re: Zenith AGM Dec 15

SanFrancisco99

posted on Oct 19, 2016 03:52PM

Well, they have at least one event planned that they haven't "confirmed" yet. Poster presentation on November 30th.

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

November 29 – December 2, 2016; Munich, Germany

The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies

S. Attwell, K. Norek, R. Jahagirdar, C. Calosing, S. Lakhotia, E. Campeau, H. Hansen

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply